Aldeyra Therapeutics (ALDX) Competitors

Aldeyra Therapeutics (NASDAQ:ALDX) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment.

Does the MarketBeat Community favor ALDX or ORGO?

Aldeyra Therapeutics received 388 more outperform votes than Organogenesis when rated by MarketBeat users. Likewise, 69.48% of users gave Aldeyra Therapeutics an outperform vote while only 65.99% of users gave Organogenesis an outperform vote.

Company	Underperform	Outperform
Aldeyra Therapeutics	Outperform Votes 485 69.48%	Underperform Votes 213 30.52%
Organogenesis	Outperform Votes 97 65.99%	Underperform Votes 50 34.01%

Do analysts rate ALDX or ORGO?

Aldeyra Therapeutics currently has a consensus price target of $9.67, indicating a potential upside of 263.41%. Organogenesis has a consensus price target of $5.50, indicating a potential upside of 20.61%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aldeyra Therapeutics is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Organogenesis	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is ALDX or ORGO more profitable?

Aldeyra Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-43.01%	-33.62%
Organogenesis	-1.62%	-2.69%	-1.63%

Which has more risk & volatility, ALDX or ORGO?

Aldeyra Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500.

Does the media favor ALDX or ORGO?

In the previous week, Aldeyra Therapeutics had 19 more articles in the media than Organogenesis. MarketBeat recorded 21 mentions for Aldeyra Therapeutics and 2 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.82 beat Aldeyra Therapeutics' score of 0.05 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do institutionals & insiders hold more shares of ALDX or ORGO?

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 8.5% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 36.9% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has higher valuation and earnings, ALDX or ORGO?

Organogenesis has higher revenue and earnings than Aldeyra Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$37.54M	-$0.94	-2.83
Organogenesis	$482.04M	1.20	$4.95M	-$0.02	-228.00

Summary

Aldeyra Therapeutics beats Organogenesis on 9 of the 17 factors compared between the two stocks.